Elegantly simple, safe and effective

BlueWillow’s intranasal platform has demonstrated safety in humans in two completed clinical trials with one trial ongoing. This platform technology overcomes the safety hurdle that slowed intranasal vaccine development for many years as the oil-in-water droplet size and other characteristics preclude CNS penetration. 

The emulsion technology is comprised of simple components including water, a natural oil, and a cationic surfactant safely used for decades in products such as mouthwash. The unique formulation approach isolates antigens within the emulsion until they are efficiently delivered to APCs (antigen-presenting-cells) for immune system processing. It’s an elegantly simple approach enabling safe and effective intranasal vaccination.